News
Celon Pharma joined the beneficiaries of the international project ORBIS – Open Research Biopharmaceutical Internships Support
The overall objective of the ORBIS project is to improve the development of innovative and generic medicines. The way to achieve this goal is the cooperation of representatives of academic institutions from various fields of pharmaceutical sciences and the research and development sector of companies. Therefore, the core of the project is the international exchangeRead more »
Current report No. 10/2022 – Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon’s esketamine DPI) in treatment-resistant bipolar depression therapy
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on April 20, 2022 an application was submitted to the Food and Drug Administration (FDA) for the granting of the Breakthrough Designation to Falkieri (Celon’s esketamine DPI) in treatment-resistant bipolar depression therapy. This application is supported by results of pre-clinical and clinical trials,Read more »
Current report No. 9/2022 – Submission of an application to the Food and Drug Administration (FDA) concerning the commencement of a clinical trial for Falkieri (Celon’s esketamine DPI)
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on April 20, 2022 an application was submitted to the Food and Drug Administration (FDA) concerning the commencement of a clinical trial for Falkieri (Celon’s esketamine DPI) as a therapy for treatment-resistant bipolar depression under the so-called Investigational New Drug (IND) Application procedure.Read more »
Current report No. 8/2022 – Allocation of A series subscription warrants to eligible persons under the Incentive Program
Current report No. 8/2022Date prepared: 2022-04-15Abbreviated name of the issuer: CELON PHARMA S.A.Subject: Allocation of A series subscription warranties to eligible persons under the Incentive Program for persons of key importance to the CompanyLegal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.Content of the report:The Management Board of CelonRead more »
Celon Pharma S.A. is a participant of the conference “Prespective Solutions for Biotechnological Medicine”
On June 20-22, 2022, Celon Pharma will take part in the international conference “Prespective Solutions for Biotechnological Medicine”, the main assumption of which will be to focus attention on the need to improve the methodology of allocation and accounting for European funds allocated to the development of research and innovative implementations, on the initiative ofRead more »
Celon Pharma S.A. Bio Forum Central European
On May 25-26, 2022, the 20th biotechnology sector fair – CEBioForum 2022 – will take place in Warsaw.As part of the conference, the President of the Management Board of Celon Pharma, Maciej Wieczorek, will take part in a discussion panel entitled “Development and funding of biotech companies”. In addition, Celon Pharma took the patronage ofRead more »
Celon Pharma S.A. at the “International Conference on Drug Sciences, ACCORD”
On May 26-28, 2022, the conference “International Conference on Drug Sciences, ACCORD” will be held. Its aim is to develop synergies between research and activities in different fields that contribute to the development of the drug. The conference will be accompanied by exhibitions of manufacturers and distributors of scientific instrumentation and laboratory equipment. On theRead more »
Jefferies initiates analytical coverage of Celon Pharma
Jefferies initiates analytical coverage of Celon Pharma, with the recommendation: Buy and the target price of PLN 37.50. The report is available to Jefferies customers. Lucy Codrington, MBChB | Equity Analyst, European HealthcareJefferies International Ltd | 100 Bishopsgate | London | EC2N 4JL |[email protected]
March 11, 2022 – Current report no. 6/2022 – Wydanie 30.000 akcji serii C w ramach warunkowego podwyższenia kapitału zakładowego
The Management Board of Celon Pharma S.A. (“Company”) informs that on March 11, 2022, 30,000 series C shares of the Company, with a nominal value of PLN 0.10 each, were entered in the securities accounts of the entitled persons, as part of the conditional increase of the Company’s share capital (“Shares”). The Shares were takenRead more »
February 21, 2022 – Current Report no. 5/2022 – Conclusion of a license purchase agreement
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.Date: February 21, 2022, time: 22:18 p.m.The Management Board of Celon Pharma S.A. (“Company”) informs that on February 20, 2022, it learned about the conclusion of an agreement with the Salk Institute for Biological Studies (“Salk”) on the purchase of a